Patient organizations' funding from pharmaceutical companies: Is disclosure clear, complete and accessible to the public? an Italian survey

Cinzia Colombo, Paola Mosconi, Walter Villani, Silvio Garattini

Research output: Contribution to journalArticle

Abstract

Background: Many patients' and consumers' organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites. Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and consumer groups' websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer groups and 17 drug companies were considered. Thirteen drug companies (76%) named at least one group funded, on their Italian websites. Of these, four (31%) indicated the activities sponsored and two (15%) the amount of funding. Of the 157 patient and consumer groups, 46 (29%) named at least one pharmaceutical company as providing funds. Three (6%) reported the amount of funding, 25 (54%) the activities funded, none the proportion of income derived from drug companies. Among the groups naming pharmaceutical company sponsors, 15 (33%) declared them in a dedicated section, five (11%) on the home page, the others in the financial report or other sections. Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups' websites. The levels of transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian pharmaceutical companies' websites, but information are often not complete.

Original languageEnglish
Article numbere34974
JournalPLoS One
Volume7
Issue number5
DOIs
Publication statusPublished - May 9 2012

Fingerprint

Disclosure
funding
Organizations
information transparency
drugs
Websites
Pharmaceutical Preparations
Financial Management
Industry
Transparency
Consumer Organizations
Surveys and Questionnaires
Drug Industry
Internet
Names
income

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Patient organizations' funding from pharmaceutical companies : Is disclosure clear, complete and accessible to the public? an Italian survey. / Colombo, Cinzia; Mosconi, Paola; Villani, Walter; Garattini, Silvio.

In: PLoS One, Vol. 7, No. 5, e34974, 09.05.2012.

Research output: Contribution to journalArticle

@article{cf1b671d24c54425b40feaef672fc7c9,
title = "Patient organizations' funding from pharmaceutical companies: Is disclosure clear, complete and accessible to the public? an Italian survey",
abstract = "Background: Many patients' and consumers' organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites. Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and consumer groups' websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer groups and 17 drug companies were considered. Thirteen drug companies (76{\%}) named at least one group funded, on their Italian websites. Of these, four (31{\%}) indicated the activities sponsored and two (15{\%}) the amount of funding. Of the 157 patient and consumer groups, 46 (29{\%}) named at least one pharmaceutical company as providing funds. Three (6{\%}) reported the amount of funding, 25 (54{\%}) the activities funded, none the proportion of income derived from drug companies. Among the groups naming pharmaceutical company sponsors, 15 (33{\%}) declared them in a dedicated section, five (11{\%}) on the home page, the others in the financial report or other sections. Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups' websites. The levels of transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian pharmaceutical companies' websites, but information are often not complete.",
author = "Cinzia Colombo and Paola Mosconi and Walter Villani and Silvio Garattini",
year = "2012",
month = "5",
day = "9",
doi = "10.1371/journal.pone.0034974",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Patient organizations' funding from pharmaceutical companies

T2 - Is disclosure clear, complete and accessible to the public? an Italian survey

AU - Colombo, Cinzia

AU - Mosconi, Paola

AU - Villani, Walter

AU - Garattini, Silvio

PY - 2012/5/9

Y1 - 2012/5/9

N2 - Background: Many patients' and consumers' organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites. Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and consumer groups' websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer groups and 17 drug companies were considered. Thirteen drug companies (76%) named at least one group funded, on their Italian websites. Of these, four (31%) indicated the activities sponsored and two (15%) the amount of funding. Of the 157 patient and consumer groups, 46 (29%) named at least one pharmaceutical company as providing funds. Three (6%) reported the amount of funding, 25 (54%) the activities funded, none the proportion of income derived from drug companies. Among the groups naming pharmaceutical company sponsors, 15 (33%) declared them in a dedicated section, five (11%) on the home page, the others in the financial report or other sections. Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups' websites. The levels of transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian pharmaceutical companies' websites, but information are often not complete.

AB - Background: Many patients' and consumers' organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites. Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and consumer groups' websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer groups and 17 drug companies were considered. Thirteen drug companies (76%) named at least one group funded, on their Italian websites. Of these, four (31%) indicated the activities sponsored and two (15%) the amount of funding. Of the 157 patient and consumer groups, 46 (29%) named at least one pharmaceutical company as providing funds. Three (6%) reported the amount of funding, 25 (54%) the activities funded, none the proportion of income derived from drug companies. Among the groups naming pharmaceutical company sponsors, 15 (33%) declared them in a dedicated section, five (11%) on the home page, the others in the financial report or other sections. Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups' websites. The levels of transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian pharmaceutical companies' websites, but information are often not complete.

UR - http://www.scopus.com/inward/record.url?scp=84860761101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860761101&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0034974

DO - 10.1371/journal.pone.0034974

M3 - Article

C2 - 22590498

AN - SCOPUS:84860761101

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e34974

ER -